Assertio’s Digital Strategy Looks To Be Paying Off

  • The company has successfully shedded its opioid businesses, $900M+ in debt and slashed well over half of its OpEx, increasing guidance three times in a year.
  • Having gotten rid of its sales force by financial necessity and pandemic force, their digital only strategy, which looked like a huge gamble, is starting to look like it’s working.
  • This model is also very leverageable and the company has already added another drug to its line-up in December.
  • The shares are cheap on basically any valuation metric, even if revenue growth can’t be taken for granted at this stage still.
  • There is also some remnant legal exposure from the opioid years, but that’s unlikely to materialize anytime soon, if ever.
  • Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »